SULAR

LOE ApproachingSM

nisoldipine

NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

Calcium Channel Antagonists

Pharmacologic Class:

Dihydropyridine Calcium Channel Blocker

Clinical Trials (5)

NCT06500364Phase 4Recruiting

Knotless Implants As an Alternative for Capsular Closure in Primary Hip Arthroscopy: a Prospective, Multi-Center Study

Started Oct 2024
NCT01888471N/ACompleted

Feasibility Study for Identifying Anti Capsular Antibody Protection Against Invasive Group B Streptococcus (GBS) Disease in Newborns of 0-6 Days Age (Early Onset Disease [EOD]) as Well as Among Infants of 7-90 Days Age (Late Onset Disease [LOD])

Started Dec 2013
3,033 enrolled
Streptococcus Agalactiae
NCT01961219N/ATerminated

Manipulation Under Anesthesia Versus Arthroscopic Capsular Release in the Treatment of Adhesive Capsulitis

Started Nov 2013
NCT00620828Phase 4Completed

The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty

Started May 2007
67 enrolled
Osteoarthritis
NCT00311870Phase 4Completed

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Started Mar 1993
52 enrolled
Diabetic Nephropathy
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.